Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Century Therapeutics (IPSC) EBITDA Margin (2022 - 2025)

Century Therapeutics (IPSC) has disclosed EBITDA Margin for 4 consecutive years, with 70.12% as the latest value for Q1 2025.

  • On a quarterly basis, EBITDA Margin rose 339304.0% to 70.12% in Q1 2025 year-over-year; TTM through Sep 2025 was 23.97%, a 473696.0% increase, with the full-year FY2024 number at 1917.59%, up 408254.0% from a year prior.
  • EBITDA Margin was 70.12% for Q1 2025 at Century Therapeutics, up from 874.84% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 70.12% in Q1 2025 to a low of 33558.59% in Q2 2023.
  • A 4-year average of 7454.93% and a median of 3733.93% in 2022 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: crashed -3128208bps in 2023, then skyrocketed 2950217bps in 2024.
  • Century Therapeutics' EBITDA Margin stood at 5861.8% in 2022, then crashed by -142bps to 14173.88% in 2023, then soared by 94bps to 874.84% in 2024, then skyrocketed by 108bps to 70.12% in 2025.
  • Per Business Quant, the three most recent readings for IPSC's EBITDA Margin are 70.12% (Q1 2025), 874.84% (Q4 2024), and 3812.77% (Q3 2024).